Risk factor
Modest price volatility
Profitability factor
Excellent dividends
About
Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, reasonably priced on P
Target Price
The average target price of LABB.MX is 21.6 and suggests 67.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i